COMMUNIQUÉS West-GlobeNewswire

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
08/06/2026
Strategic collaboration combines Nurix’s leadership in targeted protein degradation with Roche’s portfolio of B-cell targeted therapies and global clinical and commercialization footprint Robust clinical development [...]
Communiqué de presse : Sarclisa en formulation sous-cutanée de Sanofi approuvé dans l’UE comme premier traitement anticancéreux administré via un injecteur portable
08/06/2026
Sarclisa en formulation sous-cutanée de Sanofi approuvé dans l’UE comme premier traitement anticancéreux administré via un injecteur portable Sarclisa administré via l’injecteur portable CirCLIQ ® offre une expérience [...]
GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Position as a Global Biopharmaceutical Company
08/06/2026
Transaction Establishes a Large-Scale Pharmaceutical Platform in Japan and Strengthens Commercial Capabilities Across Key Therapeutic Areas TOKYO, June 07, 2026 (GLOBE NEWSWIRE) -- GNI Group Co., Ltd. (TSE: 2160) today [...]
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
08/06/2026
The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027 SAN DIEGO, June 07, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ, “LENZ” or the “Company [...]
Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis
07/06/2026
Company announcement No. 21 / 2026 Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified [...]
Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity
07/06/2026
News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP-1 dual agonist, [...]
Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist
07/06/2026
AT7687 demonstrated a favorable safety and tolerability profile with no adverse GI tolerability signals identified Once-weekly dosing potential and demonstrated target engagement across the doses tested were confirmed [...]
Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems
06/06/2026
Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM’s differentiated approach and high performance New data expands on findings shared at ATTD and [...]
Her Bodhi Claims Evaluated: What Research Reveals About This Primal Queen Alternative, Weight Loss Support and Consumer Reviews
06/06/2026
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available [...]
SKG Launches PS700 Neck Massager, Bringing Deep Kneading, Layered Heat, and Immersive Audio to Everyday Recovery
06/06/2026
The new wearable recovery device pairs deep-kneading massage, layered warmth, and immersive audio to help ease neck tension NEW YORK, June 06, 2026 (GLOBE NEWSWIRE) -- For many people, neck tension can return by the [...]
Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
06/06/2026
Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 Deep, dose-dependent B cell depletion [...]
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
06/06/2026
Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight Additional [...]
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
06/06/2026
Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes New data and real-world findings further emphasize pediatric safety, [...]
Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
06/06/2026
$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants Net proceeds anticipated to extend cash runway into first quarter of 2027, beyond [...]
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
06/06/2026
•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary [...]
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/06/2026
BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention [...]
TerrAscend Schedules Special Meeting of Shareholders in Preparation for U.S. Stock Exchange Uplisting
05/06/2026
Special meeting will allow shareholders to vote on share consolidation to support potential uplisting to a U.S. stock exchange TORONTO, June 05, 2026 (GLOBE NEWSWIRE) -- TerrAscend Corp. ("TerrAscend" or the "Company [...]
Rivus Pharmaceuticals Announces Preclinical Data for RV-8451, a Muscle-Preserving, Oral GLP-1, at ADA 2026 Scientific Sessions
05/06/2026
- Preclinical NHP data demonstrate significant fat ‑ specific weight loss with RV ‑ 8451, while preserving lean mass and showing no gastrointestinal adverse events - - IND ‑ enabling studies advancing, with IND [...]
Premier Health of America Announces Grant of Management Cease Trade Order
05/06/2026
MONTREAL, June 05, 2026 (GLOBE NEWSWIRE) -- PREMIER HEALTH OF AMERICA INC. (TSX-V: PHA) (“Premier Health” , or the “Company” ) announces that, further to its press release dated June 2, 2026, the Autorité des marchés [...]

Pages